SG90009A1 - Phosphonosulfonate compounds for treating abnomal calcium and phosphate metabolism - Google Patents

Phosphonosulfonate compounds for treating abnomal calcium and phosphate metabolism

Info

Publication number
SG90009A1
SG90009A1 SG9607956A SG1996007956A SG90009A1 SG 90009 A1 SG90009 A1 SG 90009A1 SG 9607956 A SG9607956 A SG 9607956A SG 1996007956 A SG1996007956 A SG 1996007956A SG 90009 A1 SG90009 A1 SG 90009A1
Authority
SG
Singapore
Prior art keywords
present
treating
calcium
phosphate metabolism
abnomal
Prior art date
Application number
SG9607956A
Other languages
English (en)
Inventor
Susan Mark Dansereau
Frank Hallock Ebertino
Allen Vincent Bayless
Original Assignee
Procter & Gamble Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/055,809 external-priority patent/US5731299A/en
Application filed by Procter & Gamble Pharma filed Critical Procter & Gamble Pharma
Publication of SG90009A1 publication Critical patent/SG90009A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3808Acyclic saturated acids which can have further substituents on alkyl
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/5532Seven-(or more) membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572Five-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576Six-membered rings
    • C07F9/5765Six-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576Six-membered rings
    • C07F9/58Pyridine rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576Six-membered rings
    • C07F9/59Hydrogenated pyridine rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503Five-membered rings
    • C07F9/6506Five-membered rings having the nitrogen atoms in positions 1 and 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509Six-membered rings
    • C07F9/6512Six-membered rings having the nitrogen atoms in positions 1 and 3

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Removal Of Specific Substances (AREA)
  • Materials For Medical Uses (AREA)
SG9607956A 1992-05-29 1993-05-26 Phosphonosulfonate compounds for treating abnomal calcium and phosphate metabolism SG90009A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US89088592A 1992-05-29 1992-05-29
US89088692A 1992-05-29 1992-05-29
US89149092A 1992-05-29 1992-05-29
US89148792A 1992-05-29 1992-05-29
US89130992A 1992-05-29 1992-05-29
US89135592A 1992-05-29 1992-05-29
US08/055,809 US5731299A (en) 1992-05-29 1993-05-07 Phosphonosulfonate compounds, pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism

Publications (1)

Publication Number Publication Date
SG90009A1 true SG90009A1 (en) 2002-07-23

Family

ID=27568101

Family Applications (1)

Application Number Title Priority Date Filing Date
SG9607956A SG90009A1 (en) 1992-05-29 1993-05-26 Phosphonosulfonate compounds for treating abnomal calcium and phosphate metabolism

Country Status (19)

Country Link
EP (1) EP0642518B1 (de)
JP (1) JP3781769B2 (de)
CN (3) CN1087640A (de)
AT (1) ATE169302T1 (de)
AU (1) AU659565B2 (de)
CA (1) CA2136823C (de)
CZ (1) CZ295894A3 (de)
DE (1) DE69320187T2 (de)
DK (1) DK0642518T3 (de)
ES (1) ES2123057T3 (de)
FI (1) FI945592A0 (de)
HU (1) HUT71907A (de)
IL (1) IL105839A (de)
MX (1) MX9303242A (de)
NO (1) NO305958B1 (de)
NZ (1) NZ253523A (de)
SG (1) SG90009A1 (de)
SK (1) SK145594A3 (de)
WO (1) WO1993024495A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731299A (en) * 1992-05-29 1998-03-24 The Procter & Gamble Company Phosphonosulfonate compounds, pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism
US5470845A (en) * 1992-10-28 1995-11-28 Bristol-Myers Squibb Company Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia
CA2107644A1 (en) * 1992-10-28 1994-04-29 David R. Magnin .alpha.-phosphonosulfonae squalene synthetase inhibitors and methd
US5447922A (en) * 1994-08-24 1995-09-05 Bristol-Myers Squibb Company α-phosphonosulfinic squalene synthetase inhibitors
US5618964A (en) * 1995-06-07 1997-04-08 Bristol-Myers Squibb Company Prodrug esters of phosphonosulfonate squalene synthetase inhibitors and method
CN106883165B (zh) * 2017-01-03 2019-03-26 中节能万润股份有限公司 一种模板剂中间体的制备方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4216163A (en) * 1977-03-29 1980-08-05 Benckiser-Knapsack Gmbh N-Sulfo alkane amino alkane phosphoric acids and their alkali metal salts, and a process of producing same
EP0186405A2 (de) * 1984-12-21 1986-07-02 The Procter & Gamble Company Pharmazeutische Zusammensetzungen, die geminale Diphosphonate enthalten
US4624947A (en) * 1984-09-21 1986-11-25 Henkel Kommanditgesellschaft Auf Aktien 4-dimethylamino-1-hydroxybutane-1,1-diphosphonic acid, salts thereof, and processes therefor
EP0298553A1 (de) * 1987-07-06 1989-01-11 Norwich Eaton Pharmaceuticals, Inc. Methylenphosphonalkylphosphinate, pharmazeutische Zubereitungen und Verfahren zur Behandlung abnormalen Kalzium- und Phosphat-Stoffwechsels
EP0310214A2 (de) * 1987-09-30 1989-04-05 Eli Lilly And Company 7-Substituierte bizyklische Pyrazolidinone
WO1990007513A1 (en) * 1989-01-03 1990-07-12 Gas Research Institute Fluorinated phosphonic sulfonic acids and derivatives thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731299A (en) * 1992-05-29 1998-03-24 The Procter & Gamble Company Phosphonosulfonate compounds, pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4216163A (en) * 1977-03-29 1980-08-05 Benckiser-Knapsack Gmbh N-Sulfo alkane amino alkane phosphoric acids and their alkali metal salts, and a process of producing same
US4624947A (en) * 1984-09-21 1986-11-25 Henkel Kommanditgesellschaft Auf Aktien 4-dimethylamino-1-hydroxybutane-1,1-diphosphonic acid, salts thereof, and processes therefor
EP0186405A2 (de) * 1984-12-21 1986-07-02 The Procter & Gamble Company Pharmazeutische Zusammensetzungen, die geminale Diphosphonate enthalten
EP0298553A1 (de) * 1987-07-06 1989-01-11 Norwich Eaton Pharmaceuticals, Inc. Methylenphosphonalkylphosphinate, pharmazeutische Zubereitungen und Verfahren zur Behandlung abnormalen Kalzium- und Phosphat-Stoffwechsels
EP0310214A2 (de) * 1987-09-30 1989-04-05 Eli Lilly And Company 7-Substituierte bizyklische Pyrazolidinone
WO1990007513A1 (en) * 1989-01-03 1990-07-12 Gas Research Institute Fluorinated phosphonic sulfonic acids and derivatives thereof

Also Published As

Publication number Publication date
HU9403411D0 (en) 1995-02-28
CZ295894A3 (en) 1995-10-18
DE69320187T2 (de) 1999-02-11
IL105839A (en) 2001-08-26
AU4391693A (en) 1993-12-30
CA2136823A1 (en) 1993-12-09
JPH07507314A (ja) 1995-08-10
NZ253523A (en) 1997-01-29
MX9303242A (es) 1994-05-31
NO944498L (no) 1995-01-26
CN1229083A (zh) 1999-09-22
FI945592A (fi) 1994-11-28
DK0642518T3 (da) 1998-12-14
ES2123057T3 (es) 1999-01-01
IL105839A0 (en) 1993-09-22
NO305958B1 (no) 1999-08-23
DE69320187D1 (de) 1998-09-10
FI945592A0 (fi) 1994-11-28
ATE169302T1 (de) 1998-08-15
WO1993024495A1 (en) 1993-12-09
CN1255501A (zh) 2000-06-07
EP0642518B1 (de) 1998-08-05
HUT71907A (en) 1996-02-28
NO944498D0 (no) 1994-11-24
AU659565B2 (en) 1995-05-18
CA2136823C (en) 1998-05-26
CN1087640A (zh) 1994-06-08
SK145594A3 (en) 1995-07-11
JP3781769B2 (ja) 2006-05-31
EP0642518A1 (de) 1995-03-15

Similar Documents

Publication Publication Date Title
KR100272286B1 (en) Phosphonocarboxylate compounds for treating abnormal calcium and phosphate metabolism
RU94046137A (ru) Фосфонсульфонатные соединения для лечения аномального кальциевого и фосфатного обмена, фармацевтическая композиция
CA2136820A1 (en) Thio-Substituted Nitrogen-Containing Heterocyclic Phosphonate Compounds for Treating Abnormal Calcium and Phosphate Metabolism
CA2188066A1 (en) Thio-Substituted Phosphonate Compounds
CA2136825A1 (en) Quaternary Nitrogen-Containing Phosphonate Compounds, for Treating Abnormal Calcium and Phosphate Metabolism as Well as Dental Calculus and Plaque
HUT71907A (en) Phosphonosulfonate compounds for treating abnormal calcium and phosphate metabolism
IL105836A0 (en) Quaternary nitrogen-containing phosphonate compounds and pharmaceutical compositions containing them
CA2136822A1 (en) Thio-Substituted Cyclic Phosphonate Compounds for Treating Abnormal Calcium and Phosphate Metabolism
RU94046139A (ru) Содержащие четвертичный азот фосфанатные соединения для лечения аномального кальциевого и фосфатного метаболизма, фармацевтическая композиция
RU94046103A (ru) Содержащие четвертичный азот фосфонатные соединения для лечения аномального кальциевого и фосфатного метаболизма, фармацевтическая композиция, способ лечения
RU94046138A (ru) Тиозамещенные циклические фосфонатные соединения для лечения аномального кальциевого и фосфатного метаболизма, фармацевтическая композиция, способ лечения